ALS Ltd (ASX: ALQ) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

ALS Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $11.49 billion
P/E Ratio 43.88
Dividend Yield 1.63%
Shares Outstanding 507.54 million
Earnings per share 0.547
Dividend per share 0.39
Year To Date Return 8.89%
Earnings Yield 2.28%
Franking 29.8969072165
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

ALS Ltd (ASX: ALQ)
Latest News

excited person holding australian cash in both hands
Dividend Investing

3 ASX 200 shares trading ex-dividend next week  

If you want to receive the payouts, you’ll need to own these ASX 200 shares at least one day before…

Read more »

a female archer looking rustic and slightly dishevelled is in extreme close up as she draws back her bow and narrows her eye to aim for a target .
Dividend Investing

22 high-yield ASX dividend shares Wilsons is targeting

Analysts warn finding excellent income-producing stocks is not just about going for the highest yields.

Read more »

ASX share
Industrials Shares

2 under-the-radar ASX shares to pounce on right now: expert

You can't just buy the stocks that everyone else has if you want to beat the market. Here's a couple…

Read more »

A group of businesspeople clapping.
Share Market News

Here are the top 10 ASX shares today

We run down the biggest gainers on Thursday.

Read more »

A young woman sits on her lounge looking pleasantly surprised at what she's seeing on her laptop screen as she reads about the South32 share price
Industrials Shares

Guess how much one insider spent on this ASX 100 share in the past week

This director thinks ALS shares are too good to pass up.

Read more »

Two people shaking hands in the boardroom on a merger.
Mergers & Acquisitions

HRL share price jumps 10% as board backs takeover from ALS

HRL has accepted ALS' takeover offer...

Read more »

A little girl with red hair runs excitedly with a rocket strapped to her back, trying to launch.
Mergers & Acquisitions

Guess which small-cap company is soaring 71% on a takeover bid from an ASX 200 share

ALS’ non-binding takeover offer represents a massive premium on HRL’s recent share price.

Read more »

A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
Dividend Investing

3 ASX 200 shares trading ex-dividend today

These ASX 200 shares are ex-dividend on Monday.

Read more »

Computer key - Top 10 ASX today
Share Market News

Here are the top 10 ASX shares today

Here are your top 10 biggest gainers in the ASX 200 on Thursday.

Read more »

Green arrow going up on stock market chart, symbolising a rising share price.
Share Gainers

Why ALS, Appen, Objective Corp, and WiseTech shares are pushing higher

These ASX shares are on form on Thursday...

Read more »

Green arrow going up on stock market chart, symbolising a rising share price.
Share Gainers

Why ALS, Costa, Superloop, and Worley shares are charging higher

These ASX shares are on form on Wednesday...

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 ASX shares rated 'buy' by this top fund manager

Top analysts at WAM have outlined two compelling ASX shares.

Read more »

Frequently Asked Questions

Yes, ALS Ltd historically pays two partially or fully franked dividends a year.

ALS Ltd generally pays its shareholder dividends in July and December

ALS Ltd listed on the ASX on 18 July 1952.

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
26 Nov 2025 $0.1940 29.90% Interim 17 Dec 2025
03 Jul 2025 $0.1970 30.00% Final 25 Jul 2025
27 Nov 2024 $0.1890 30.00% Interim 19 Dec 2024
12 Jun 2024 $0.1960 20.00% Final 02 Jul 2024
23 Nov 2023 $0.1960 20.00% Interim 14 Dec 2023
09 Jun 2023 $0.1940 10.00% Final 06 Jul 2023
24 Nov 2022 $0.2030 0.00% Interim 16 Dec 2022
06 Jun 2022 $0.1700 30.00% Final 04 Jul 2022
02 Dec 2021 $0.1580 30.00% Interim 17 Dec 2021
07 Jun 2021 $0.1460 70.00% Final 05 Jul 2021
26 Nov 2020 $0.0850 100.00% Interim 16 Dec 2020
05 Jun 2020 $0.0610 70.00% Final 06 Jul 2020
27 Nov 2019 $0.1150 30.00% Interim 16 Dec 2019
03 Jun 2019 $0.1150 35.04% Final 01 Jul 2019
29 Nov 2018 $0.1100 20.00% Interim 18 Dec 2018
06 Jun 2018 $0.0900 40.00% Final 02 Jul 2018
29 Nov 2017 $0.0800 40.00% Interim 18 Dec 2017
07 Jun 2017 $0.0000 0.00% Final 03 Jul 2017
05 Dec 2016 $0.0550 60.00% Interim 21 Dec 2016
08 Jun 2016 $0.0600 40.00% Final 01 Jul 2016
03 Dec 2015 $0.0750 25.07% Interim 18 Dec 2015
11 Jun 2014 $0.2000 50.00% Final 02 Jul 2014
07 Jun 2013 $0.2700 50.00% Final 02 Jul 2013
05 Jun 2009 $0.4250 0.00% Final 01 Jul 2009
01 Dec 2008 $0.4250 58.82% Interim 17 Dec 2008
06 Jun 2008 $0.5100 58.82% Final 01 Jul 2008
30 Nov 2007 $0.2975 58.82% Interim 17 Dec 2007
06 Jun 2007 $0.3570 58.82% Final 02 Jul 2007
29 Nov 2006 $0.2380 58.82% Interim 15 Dec 2006
05 Jun 2006 $0.2900 100.00% Final 03 Jul 2006
25 Nov 2005 $0.2100 100.00% Interim 20 Dec 2005
04 Jun 2004 $0.1900 100.00% Final 01 Jul 2004
28 Nov 2003 $0.1400 100.00% Interim 19 Dec 2003

ALQ ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About ALS Ltd

ALS Ltd (ASX: ALQ) is one of the world's largest laboratory testing, inspection, certification, and verification businesses. It operates from around 350 sites across 65 countries.

Listed on the ASX in 1952, ALS operates three divisions: commodities, life sciences, and industrial. ALS's commodities segment traditionally generates the majority of the company's underlying earnings. It provides geochemistry, metallurgy, inspection, and mine site services for the mining industry globally.

The company also provides environmental, pharmaceutical, and food and beverage testing and certification. ALS Ltd has a multi-billion dollar market capitalisation and is part of the ASX 100.

ALQ Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
09 Mar 2026 $22.63 $-1.37 -5.71% 1,873,507 $23.19 $23.39 $22.48
06 Mar 2026 $24.00 $-0.47 -1.92% 1,424,205 $23.65 $24.38 $23.65
05 Mar 2026 $24.47 $-0.10 -0.41% 1,983,525 $25.00 $25.11 $24.05
04 Mar 2026 $24.57 $-1.02 -3.99% 2,065,813 $25.29 $25.49 $24.22
03 Mar 2026 $25.59 $-0.45 -1.73% 1,550,487 $25.85 $26.05 $25.33
02 Mar 2026 $26.04 $0.42 1.64% 1,628,110 $25.72 $26.17 $25.35
27 Feb 2026 $25.62 $0.14 0.55% 1,538,634 $25.03 $25.83 $24.80
26 Feb 2026 $25.48 $0.18 0.71% 1,233,909 $25.50 $25.66 $25.29
25 Feb 2026 $25.30 $0.36 1.44% 1,744,076 $24.94 $25.38 $24.67
24 Feb 2026 $24.94 $0.64 2.63% 1,510,218 $24.75 $25.05 $24.00
23 Feb 2026 $24.30 $-0.27 -1.10% 746,230 $24.57 $24.84 $24.22
20 Feb 2026 $24.57 $-0.06 -0.24% 640,121 $24.27 $24.63 $24.12
19 Feb 2026 $24.63 $0.69 2.88% 1,432,152 $24.38 $24.63 $23.99
18 Feb 2026 $23.94 $0.09 0.38% 908,772 $23.72 $24.01 $23.62
17 Feb 2026 $23.85 $0.03 0.13% 536,496 $23.90 $24.01 $23.62
16 Feb 2026 $23.82 $-0.20 -0.83% 2,178,574 $24.10 $24.16 $23.68
13 Feb 2026 $24.02 $-0.51 -2.08% 1,680,649 $24.55 $24.71 $23.79
12 Feb 2026 $24.53 $-0.09 -0.37% 1,682,567 $24.65 $24.87 $24.35
11 Feb 2026 $24.62 $0.47 1.95% 912,141 $24.50 $24.66 $24.27
10 Feb 2026 $24.15 $0.69 2.94% 1,623,831 $24.00 $24.23 $23.65
09 Feb 2026 $23.46 $0.51 2.22% 1,435,701 $22.95 $23.57 $22.85

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
02 Dec 2025 Malcom Deane Sell 7,356 $161,317
On-market trade. As per annouuncement on 05-12-2025
26 Aug 2025 Siddhartha Kadia Buy 4,910 $59,236
On-market trade. US$
14 Aug 2025 Nigel Garrard Buy 1,328 $24,966
On-market trade.
07 Aug 2025 Erica Mann Buy 5,930 $108,044
On-market trade.
30 Jul 2025 Malcom Deane Issued 146,884 $2,396,926
Issue of securities. valued, 517690 RIGHTS
01 Jul 2025 Malcom Deane Expiry 9,514 $162,403
As advised by the company. 389,379 Rights. Lapse of Performance Rights
01 Jul 2025 Malcom Deane Exercise 31,939 $545,198
Conversion of securities. 370,806 rights. estimated value
01 Jul 2025 Malcom Deane Issued 13,366 $218,113
Issue of securities. 402,745 Rights, estimated value
01 Jul 2025 Malcom Deane Buy 31,939 $545,198
Conversion of securities. estimated value
01 Jul 2025 Malcom Deane Buy 1,761 $29,067
Participation in share purchase plan. As per announcement on 4 July 2025. Security Purchase Plan
27 Jun 2025 Peter Possemiers Issued 1,212 $20,000
Participation in share purchase plan.
27 Jun 2025 Nigel Garrard Issued 1,818 $30,000
Participation in share purchase plan.
12 Jun 2025 Nigel Garrard Buy 2,000 $33,100
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Nigel David Garrard Non-Executive Deputy ChairmanNon-Executive Director Jun 2023
Mr Garrard is an executive with a record across the fast-moving consumer goods and industrial/manufacturing sectors. He has over 20 years of experience as an ASX-listed CEO across three companies. In 2019, he retired as Managing Director and CEO of Orora Limited. He led the demerger of Orora Limited from Amcor, and the subsequent listing of Orora Limited on ASX in 2013. He was President of the Amcor Australasia and Packaging Distribution business group, Managing Director of Coca-Cola Amatil's Food and Services Division, and Managing Director of SPC Ardmona. Nigel brings international experience across listed, not-for-profit, government and private entities. He is currently the Chairman of Ansell Limited, Chairman of Flinders Port Holdings Pty Ltd, Chairman of the McMahon Services advisory board, and Director of Treasury Wine Estates Limited.
Dr John Francis Mulcahy Non-Executive Director Feb 2012
Mr Mulcahy is Chairman of Orix Australia Corporation Limited, an unlisted public company (appointed March 2016). He is also a current Non-Executive Director of various Zurich Australia Insurance subsidiaries and GWA Group Limited. John was previously a director and Chairman of both Mirvac Group Limited (November 2009 - December 2022), Coffey International Limited (September 2009 - January 2016). He is a former Guardian of the Future Fund of Australia and former Managing Director and Chief Executive Officer of Suncorp-Metway Limited. Prior to Suncorp, John held several senior executive roles at the Commonwealth Bank and Lend Lease Corporation. He is a member of the Sustainability and Innovation Committee.
Ms Christina (Christy) Boyce Non-Executive Director Sep 2025
Ms Boyce has two decades experience in various senior roles across multiple industries and geographies.
Ms Leslie A Desjardins Non-Executive Director Nov 2019
Ms Desjardins has a background as a CFO and senior financial and governance professional in a range of large multinational and global businesses. She has commercial and financial governance expertise with large multinational public companies in North America, Canada, and Australia each with global operations. Her areas of expertise include CFO level executive and financial strategic leadership, M&A, corporate finance and treasury, governance, financial and tax compliance, and enterprise risk management. Leslie is currently a Director, Audit Committee Chair, Human Resource Committee member with Ansell Limited. During her executive career, Leslie served as Executive VP and CFO at Amcor Limited, a global leader in packaging of food, beverage, pharmaceutical and tobacco products. Prior to Amcor Ltd, Leslie served in financial and corporate strategic positions with General Motors Corporation, including Chief Financial Officer GM Holden Australia, Controller GM North America, Executive Director Manufacturing Finance and Director GM North America Strategy and Planning. She is the Chair of the Risk Committee and from April 2025 a member of the People Committee. In FY25, Leslie was a member of the Sustainability and Innovation Committee.
Dr Siddhartha Kadia Non-Executive Director Jan 2019
Mr Kadia is currently CEO and Director at Calibre Scientific, a privately held company that services life sciences tools industry. Siddhartha has lived and worked in the US, Japan, China, and India and has more than 20 years of international experience as a company director, executive and technical leader in the Life Sciences and TIC (testing, inspection and certification) sectors. Siddhartha was formerly President and CEO of EAG Laboratories, a global scientific testing company headquartered in San Diego, California. He has also been a Director of USA-listed companies Newport Corporation (NSDQ: NEWP), Volcano Corporation (NSDQ: VOLC), Isoplexis Corporation (NSDQ:ISO), Berkeley Lights (NDSQ:BLI), Horizon Discovery Group (LSW:HZD), Nuvasive, Inc (NSDQ: NUVA). Siddhartha was also a management consultant at McKinsey & Company where his work focused on various life sciences and healthcare related engagements. He is the Chair of the Sustainability and Innovation Committee, a member of the People Committee.
Ms Erica Mann Non-Executive Director Mar 2024
Ms Mann is a C-suite executive with a 30- year career across complex, highly regulated, multi-channel and multi-product environment in top DAX, NYSE, NSDAQ pharmaceutical, OTC and FMCG multinationals. Before retiring as an executive, Erica led Bayer's Consumer Health Division, one of the world's largest OTC companies with 6 billion euro in turnover. Prior to joining Bayer, she was President and General Manager of Pfizer Nutrition following its acquisition of Wyeth Inc, where she served as Senior Vice President of Global Nutrition. This followed the other senior executive roles of other Fortune 500 companies including Eli-Lily and Johnson & Johnson. She has held leadership positions in South Africa, Australia, New Zealand, Germany, Switzerland and the US. In addition to her executive experience in the nutrition and health industry, Erica has experience with global and emerging markets across Africa, China, Russia, and Brazil. Erica currently serves as an independent director of Kenvue, DSM-Firmenich and Kellogg where she is a member of the Audit, and Social Responsibility & Public Policy Committees. She is a member of the Sustainability and Innovation Committee.
Mr Peter Possemiers Non-Executive Director Nov 2022
Mr Possemiers has a background as a TIC sector expert with almost 40 years of experience working as a senior executive in leadership roles globally for SGS. He has lead teams both regionally and globally most notably SGS's global Environment Health and Safety business, then a CHF 550 million business with a global headcount which exceeded 6000. As Executive Vice President, he was a member of the SGS Operations Council with responsibility for the strategic growth and profitability of the business, leading 15 strategic acquisitions. He moved into management roles in Singapore, Philippines, China and Korea, where he established and developed new markets including food, pharma, and mobile technology. In 2013, Peter was promoted to Executive Vice President, Global Environment, Health & Safety, a position based in Switzerland which he held for 8 years before moving into his most recent role as Vice President, Strategic Integration in 2021 following the acquisition of the Synlab A&S business, which covered the environmental, food, pharma and oil condition monitoring testing sector across Europe. He is the Chair of the People Committee, and a member of the Risk Committee.
Mr Malcom Deane Chief Strategy Officer General Manager Life Sciences - Food & Pharma Americas GeneralChief Executive OfficerManaging Director Mar 2023
Mr Deane has served the company in various executive positions for the past 10 years in such roles as General Manager for Life Sciences Latin America, Food & Pharma Americas, and most recently as the Chief Strategy Officer, leading corporate strategy, business development and acquisitions.
Ms Catharine Farrow Non-Executive Director Mar 2025
Dr Farrow is a director of Franco-Nevada and has more than 30 years of mining industry experience in all aspects of exploration, development, technical services, acquisitions, company building, operations, board governance and innovation/technology. Her experience ranges from the High Arctic to equatorial environments in base, critical and precious metals. Catharine Farrow also serves as a director of Eldorado Gold Corporation, is lead director of Aclara Resources Inc., and until November 2024, was on the Board of Centamin PLC. She is also active in the mining and technology industries in both public and private companies, and academia as President of FarExGeoMine Ltd., where she provides advisory support in technical, governance, innovation and technology, organizational structure and as an expert witness. Previously she had been COO of KGHM International and held various other executive roles in precursor companies from 2003 to 2012 including as Chief Technology Officer and Senior Vice President Corporate Development and Technical Services (including joint ventures, M&A opportunities, and strategy). She is a member of the Sustainability and Innovation Committee.
Ms Dayna Field Company SecretaryGeneral Counsel Oct 2024
-
Stuart Hutton Chief Financial Officer
-
Dayna Field Company SecretaryGeneral Counsel
-
Tim Kilmister GM Environmental
-
Andreas Jonsson GM Food & Pharma
-
Bruce McDonald GM Geochemistry
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
No Top 20 Shareholder 0 0.00%

Profile

since

Note